Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
1. |
ECCT/25/10/01 | H06_04TP A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years after vaccination in African children. |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya KEMRI CRC WRP KERICHO |
View |
2. |
ECCT/25/08/03 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Uasin Gishu county) 3. KEMRI-WRP (Kericho county) 4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county) |
View |
3. |
ECCT/25/05/13 | IVI CCV 002 A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region |
Principal Investigator(s) 1. Walter Jaoko Site(s) in Kenya KAVI - Institute of Clinical Research, University of Nairobi |
View |
4. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
View |
5. |
ECCT/25/03/03 | ALIM STUDY Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial. |
Principal Investigator(s) 1. Dr. QUENTIN AWORI Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
View |